---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-037608"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:03:00.083499+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences reports Q4 net loss of $59.5M; outlines Phase 3 plans for tarcocimab and KSI-501

## Summary
- Q4 2023 net loss $59.5M ($1.13/share) vs $70.4M ($1.35/share) in Q4 2022; R&D expenses fell to $46.6M.
- Cash and equivalents $285.5M; company believes sufficient to fund operations into 2026.
- Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively enrolling; uses go-to-market formulation.
- Phase 3 DAYBREAK study in wet AMD (KSI-501 vs tarcocimab vs aflibercept) targeted to start mid-2024 after FDA discussions.
- Phase 1b study of KSI-101 planned for Q2 2024; dual pivotal studies targeted for later 2024.

## SEC filing metadata
- accession: 0000950170-24-037608
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017024037608/0000950170-24-037608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017024037608/kod-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-037608
- JSON: https://secwatch.observer/filing/0000950170-24-037608.json
- Plain text: https://secwatch.observer/filing/0000950170-24-037608.txt

## Key facts
- Earnings Releases
  Kodiak Sciences Inc. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 28, 2024, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2023 and business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468748/000095017024037608/0000950170-24-037608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.